Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: a 20‐year real‐world study
| Autor: | Andrea Borenich, Christoph Högenauer, Lukas Binder, Patrizia Kump, Andreas Blesl, Franziska Baumann-Durchschein, Wolfgang Petritsch, Sigrid Mestel, Gudrun Pregartner, Andrea Berghold, Heimo H. Wenzl |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Inflammatory bowel disease 03 medical and health sciences 0302 clinical medicine Internal medicine Adalimumab Humans Medicine Pharmacology (medical) 030212 general & internal medicine Treatment Persistence with Anti‐tnf Agents in IBD Retrospective Studies Hepatology business.industry Proportional hazards model Hazard ratio Gastroenterology Retrospective cohort study Inflammatory Bowel Diseases medicine.disease Ulcerative colitis Infliximab Cohort Original Article Colitis Ulcerative Female Tumor Necrosis Factor Inhibitors 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Alimentary Pharmacology & Therapeutics |
| ISSN: | 1365-2036 0269-2813 |
| Popis: | Summary Background Anti‐TNF antibodies were the first biologic treatment option for patients with inflammatory bowel diseases. Aims To assess length of treatment persistence of first anti‐TNF therapy and influencing factors used in the standard care of patients with inflammatory bowel diseases. Methods Single‐centre, retrospective study from a register including patients who received anti‐TNF therapy in the last 20 years at the study centre. Kaplan‐Meier analysis with log‐rank test was used to describe treatment persistence. With multivariable Cox regression analysis, risk factors for treatment failure were investigated. Results Five hundred thirty‐eight patients (CD, Crohn's disease: 367, UC, ulcerative colitis: 147, inflammatory bowel disease unclassified: 24) with a median follow‐up of 8.1 years were included. Median (95% confidence interval) treatment persistence in the total cohort was 2.3 years (28 [22, 38] months), and nearly half of patients withdrew from treatment within 2 years. Male patients were treated longer than females (male: 37 [25, 48] months, female: 23 [14, 33] months, P = 0.002). Treatment persistence was longer in CD compared to UC (CD: 39 [30, 50] months, UC: 13 [9, 19] months, P At the end of follow‐up, only 29% of patients still received scheduled treatment with the first anti‐TNF. Longer treatment persistence could be observed in males, in patients with Crohn's disease and for adalimumab treatment in Crohn's disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text